Building a clinical platform for response-guided geroscience: safety and feasibility in the randomized ELITE pilot trial
The ELITE pilot trial demonstrated the safety and operational feasibility of an integrated clinical platform for response-guided geroscience, achieving high adherence and low dropout rates among 31 midlife and older adults while successfully combining repurposed metabolic drugs, investigational supplements, and dense longitudinal data collection.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Aging is not a single event but a slow, complex drift of the body's systems. For decades, scientists have searched for ways to slow this drift, a field known as geroscience. The central idea is that by understanding how the body changes over time, we might be able to intervene to keep people healthier for longer. However, testing these ideas has been difficult. Traditional medical trials often look at large groups of people to find an average effect, like measuring how much a drug lowers blood pressure in a crowd. This approach misses the individual story. It cannot easily see if a specific person is getting better, staying the same, or getting worse, nor can it tell us exactly when those changes happen. To truly personalize aging interventions, researchers need a way to watch a single person's health journey closely, day by day, while they take treatment. They need a system that connects what a person takes with how their body responds, all while keeping a strict watch on safety.
This is the challenge that the ELITE pilot trial set out to solve. Researchers from institutions including Sheba Medical Center in Israel, Stanford University, and others built a new kind of clinical platform designed to track individual responses in real time. They wanted to know if it was even possible for adults in midlife and older age to handle a demanding routine that combined several different medicines, daily digital check-ins, and frequent medical tests. The goal was not just to see if a treatment worked, but to prove that the entire system of watching, measuring, and adjusting could work safely and reliably in the real world. The study focused on thirty-one adults between the ages of fifty and eighty who did not have diabetes but were at risk for metabolic issues. They were given a regimen that included repurposed metabolic drugs—medicines originally designed for other conditions but used here to support healthy aging—along with two investigational supplements. The participants also used a smartphone app every day to log their intake and capture images of their tongue, face, eyes, and wrist, creating a dense stream of data about their daily state.
The results of this eight-week pilot were a clear demonstration that such a complex system is feasible. Nearly every participant finished the study. Thirty out of the thirty-one people who started the trial completed the full eight weeks, a completion rate of nearly ninety-seven percent. This was a critical test, as the researchers had set a benchmark that fewer than twenty percent of people should drop out for the system to be considered practical. In terms of sticking to the plan, the participants did exceptionally well. On average, they followed the protocol more than ninety percent of the time. This included taking their pills and liquids, using the app to scan their bodies, and attending their scheduled medical visits. The digital tracking was particularly robust, with participants capturing data on more than ninety-one percent of the days they were supposed to. Even the one person who had to stop taking the treatment early because they could not manage the home scanning on their own remained in the study for follow-up, showing that the system could handle interruptions without losing the person entirely.
Safety was the other major pillar of the investigation, and the trial confirmed that this intensive approach was safe for the participants. Throughout the eight weeks, there were no serious adverse events, no hospitalizations, and no deaths. Some participants did experience mild side effects, such as stomach upset or fatigue, which is common when taking new medications. These issues were minor and manageable; in a few cases, a specific part of the treatment was paused or stopped, but the participants continued with the rest of the study and the medical monitoring. The researchers found that the combination of drugs and supplements did not cause unexpected harm, and the system of daily checks allowed the medical team to spot and address any concerns immediately. This proved that it is possible to give older adults a mix of metabolic therapies and watch them closely without putting them at significant risk.
The study also validated the technology behind the new platform. The app successfully collected thousands of digital records, including images and voice recordings, which were linked to specific times and the treatments the participants had taken. This created a detailed, traceable record of what happened to each person. The researchers used this data to generate a score that estimated whether a participant was improving, staying the same, or declining. While this pilot trial did not change the treatment based on these scores, the system successfully generated them and presented them to the doctors for review. This showed that the machinery for response-guided medicine—the ability to see a change, interpret it, and potentially act on it—can function as intended. The data collected, which included blood samples, stool samples, and molecular analyses, is now ready to be studied in depth to see exactly how the treatments affected the participants' biology.
The success of the ELITE trial suggests that the future of aging research can move beyond simple averages. It demonstrates that a system combining daily digital observation, periodic medical testing, and careful clinical oversight can be delivered safely to older adults. The participants proved that they could sustain the demands of this new way of doing science, and the researchers proved that the tools to track them work. This paves the way for larger, longer studies where doctors can actually adjust treatments based on how an individual is responding. Instead of guessing what works for a group, this approach allows medicine to see what works for a person, moment by moment. The trial did not solve the problem of aging, nor did it prove that the specific drugs used will extend life. What it did prove is that the path to finding those answers is open, and that we now have a practical, safe way to walk it.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.